Recombinant proteins are the mainstay of biopharmaceuticals. A key challenge in the
manufacturing and formulation of protein biologic products is the tendency for the active …

In cancer, non-synonymous DNA base changes alter protein sequence and produce
neoantigens that are detected by the immune system. For immune detection, neoantigens …

Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes
derived from recurrently mutated driver genes. Here we describe a high-throughput platform …

CD8+ T cell recognition of peptide epitopes plays a central role in immune responses
against pathogens and tumors. However, the rules that govern which peptides are truly …

Neoepitopes arising from amino acid substitutions due to single nucleotide polymorphisms
are targets of T cell immune responses to cancer and are of significant interest in the …

Interest in MHC-E–restricted CD8+ T cell responses has been aroused by the discovery of
their efficacy in controlling simian immunodeficiency virus (SIV) infection in a vaccine model …

Human leukocyte antigen (HLA)-E binds epitopes derived from HLA-A, HLA-B, HLA-C and
HLA-G signal peptides (SPs) and serves as a ligand for CD94/NKG2A and CD94/NKG2C …

HLA-E is a non-classical class I MHC protein involved in innate and adaptive immune
recognition. While recent studies have shown HLA-E can present diverse peptides to NK …

Complete cancer regression occurs in a subset of patients following adoptive T cell therapy
(ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs). However, the low success …

T-cell recognition of peptides incorporating nonsynonymous mutations, or neoepitopes, is a
cornerstone of tumor immunity and forms the basis of new immunotherapy approaches …